Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioAdaptives, Inc. (BDPT) SEC filings page on Stock Titan is intended to provide access to the company’s regulatory disclosures once they are available through the EDGAR system. While no specific SEC filings are listed in the provided data, this page is designed to aggregate documents such as annual reports, quarterly reports, and ownership filings as they are filed with the U.S. Securities and Exchange Commission.
For a company in the nutraceutical and biotechnology-focused wellness space, filings like Form 10-K and Form 10-Q, when present, typically describe business lines that include cognitive-support supplements such as MyndMed™, adaptogenic nootropics like NeuroRush™, weight management products such as Zeranovia™, and pet wellness offerings under the PawPa™ brand. These documents can give investors structured insight into product strategies, research activities, and risk factors.
Ownership and insider activity, when reported on forms such as Form 3 and Form 4, can help readers understand how directors, officers, and significant shareholders are trading BDPT shares. Proxy statements, when available, may outline governance practices and compensation policies linked to BioAdaptives’ focus on health and wellness solutions.
Stock Titan enhances this information with AI-powered tools that summarize lengthy filings, highlight key sections, and make it easier to locate discussions of product pipelines, clinical trials, or strategic initiatives referenced in BioAdaptives’ public communications. As new BDPT filings are released on EDGAR, this page is updated so that investors and researchers can review the underlying regulatory documents alongside AI-generated explanations.
BIOADAPTIVES, INC. director Mark P. Frissora reported an other-type derivative transaction involving Series D Convertible Preferred Stock. He received 4,386 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.0000 per share.
Each preferred share is convertible into 100 shares of common stock, for 438,600 underlying common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted until six months after issuance, except upon liquidation, and each preferred share carries 100 votes on matters submitted to stockholders. Following this grant, Frissora directly holds 66,746 shares of Series D Convertible Preferred Stock.
BioAdaptives, Inc. submitted a Form 12b-25 notification stating it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes the delay to completing disclosures and finalizing financial statements with its independent public accountant. The notice is signed by James E. Keener, CEO on March 31, 2026.
BIOADAPTIVES, INC. director Mark P. Frissora reported an "other" transaction involving Series D Convertible Preferred Stock. He received 2,578 shares of this preferred stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.00 per share, bringing his direct holdings to 62,360 shares.
Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation, and generally cannot be converted for six months after issuance except upon liquidation. Each preferred share carries 100 votes on company matters, and the conversion right does not expire.
Bioadaptives, Inc. reported that director Mark P. Frissora received 2,565 shares of its Series D Convertible Preferred Stock on February 1, 2026, coded as a transaction "J" and issued at $0.00 per share as compensation for board services.
Following this grant, Frissora beneficially owns 59,779 Series D preferred shares. Each Series D share is convertible into 100 common shares, subject to a 4.9% beneficial ownership limitation, cannot be converted until six months after issuance (except on liquidation), carries 100 votes per share, and has a conversion right that does not expire.
BioAdaptives, Inc. director reports stock-based board compensation. A company director received 2,286 shares of BioAdaptives Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share has a stated par value of $0.0001 and is convertible into 100 shares of common stock, for an underlying 228,600 common shares, subject to a 4.9% beneficial ownership limitation.
No Series D shares may be converted until six months after issuance, except that conversion occurs immediately upon liquidation. Each preferred share carries 100 votes in stockholder matters, and the conversion right does not expire. Following this transaction, the reporting person held 57,217 derivative securities in the form of Series D Convertible Preferred Stock, owned directly.
Bioadaptives, Inc. disclosed that a director filed a Form 4 reporting equity compensation in the form of preferred stock. On 12/01/2025, the director received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share is convertible into 100 shares of common stock, for a total of 202,500 underlying common shares, but conversions are subject to a 4.9% beneficial ownership limitation.
The preferred shares generally cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters and the conversion right does not expire. After this transaction, the reporting person beneficially owned 54,931 derivative securities, held directly.
BioAdaptives, Inc. (BDPT) reported Q3 2025 results, showing a wider net loss and continued liquidity pressure. Net loss was $379,502 for the quarter, compared with $37,649 a year ago, as operating expenses and derivative fair value changes weighed on results. Revenue reached $4,632 in Q3 as limited PawPa Regen sales began.
For the nine months, net loss totaled $734,552 on revenue of $7,851. Cash was $59,273 at September 30, 2025, with current assets of $108,860 versus current liabilities of $1,589,570, resulting in a working capital deficiency of $1,480,710. The company reported a stockholders’ deficit of $1,465,210, including derivative liabilities of $967,406 and convertible notes of $359,300.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and noted material weaknesses in internal controls. Financing activities included $300,000 of cash proceeds from Series D preferred stock and debt-to-equity conversions. Common shares outstanding were 12,008,659 as of October 17, 2025.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.
Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on 10/01/2025. He was issued 1,517 shares of Series D Convertible Preferred Stock as board-service compensation under a Board of Directors Agreement dated 02/03/2025. Each preferred share converts into 100 shares of common stock, so the issuance represents economic exposure to 151,700 common shares, subject to a 10% beneficial ownership cap. Conversions are restricted for six months from issuance (except on liquidation), and each Series D preferred share carries 100 votes at stockholder meetings. The reporting indicates direct ownership following the transaction and no cash price was paid for the preferred shares.